Inventiva (ADR)
Developing lanifibranor, an oral MASH candidate, through a pivotal global trial.
$4.71
After-hours close0.00 (0.00%)
At close$4.71(−3.98%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 100.73%Insiders —
Shares outstanding 51.98M · Float 43.97M · 84.6% free float
Institutions13F, as of Mar 31, 2026
66 holders · 52.36M shares · 23 new positions · 44 increased · 10 reduced · 10 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Samsara Biocapital, LLC | 5.19M | 9.99% | 0 | May 15, 2026 |
| Caligan Partners LP | 4.97M | 9.57% | +2.97M | May 15, 2026 |
| Paradigm Biocapital Advisors LP | 4.00M | 7.69% | 0 | May 15, 2026 |
| Millennium Management LLC | 2.99M | 5.75% | +335.0K | May 15, 2026 |
| Trails Edge Capital Partners, LP | 2.66M | 5.11% | 0 | May 15, 2026 |
| Franklin Resources Inc | 2.46M | 4.74% | −38.6K | May 13, 2026 |
| 2.35M | 4.53% | −246.0K | May 12, 2026 | |
| UBS Group AG | 2.32M | 4.46% | −325.0K | May 5, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Invus Public Equities, L.P. | 10.60% | 14.81M | 13G | Jul 31, 2025 ↗ |
| Andera Partners | 7.70% | 14.11M | 13G | Feb 17, 2026 ↗ |
| Sofinnova Crossover I SLP | 5.60% | 12.33M | 13G | Feb 17, 2026 ↗ |
| Yiheng Capital Partners, L.P. | 5.46% | 7.60M | 13G | Nov 13, 2025 ↗ |
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.